In ovarian cancer, MIR193A is silenced by methylated modification and down regulation of MIR193A expression promotes tumor aggressiveness by losing function of targeting GRB7 and MAPK/ERK pathways (Chen et al., 2018). Here, MIR193A is linked to ovarian carcinoma.